Latest news with #Delaware
Yahoo
10 minutes ago
- Business
- Yahoo
Sussex County home listings asked for more money in May - see the current price here
The median home in Sussex County listed for $559,000 in May, up 1.7% from the previous month's $549,950, an analysis of data from shows. Compared with May 2024, the median home list price decreased 2.4% from $572,450. The statistics in this article only pertain to houses listed for sale in Sussex County, not houses that were sold. Information on your local housing market, along with other useful community data, is available at Sussex County's median home was 2,175 square feet, listed at $260 per square foot. The price per square foot of homes for sale is mostly unchanged from May 2024. New Castle County : Home listings asked for more money in May - see the current median price here Kent County: Home listings asked for less money in May - see the current median price here Listings in Sussex County moved slowly, at a median 57 days listed compared with the May national median of 51 days on the market. In the previous month, homes had a median of 49 days on the market. Around 660 homes were newly listed on the market in May, a 7.8% increase from 612 new listings in May 2024. The median home prices issued by may exclude many, or even most, of a market's homes. The price and volume represent only single-family homes, condominiums or townhomes. They include existing homes, but exclude most new construction as well as pending and contingent sales. Across the Philadelphia-Camden-Wilmington metro area, median home prices rose to $385,000, slightly higher than a month earlier. The median home had 1,616 square feet, at a list price of $233 per square foot. In Delaware, median home prices were $499,000, a slight increase from April. The median Delaware home listed for sale had 2,100 square feet, with a price of $238 per square foot. Throughout the United States, the median home price was $440,000, a slight increase from the month prior. The median American home for sale was listed at 1,840 square feet, with a price of $234 per square foot. The median home list price used in this report represents the midway point of all the houses or units listed over the given period of time. Experts say the median offers a more accurate view of what's happening in a market than the average list price, which would mean taking the sum of all listing prices then dividing by the number of homes sold. The average can be skewed by one particularly low or high price. The USA TODAY Network is publishing localized versions of this story on its news sites across the country, generated with data from Please leave any feedback or corrections for this story here. This story was written by Ozge Terzioglu. Our News Automation and AI team would like to hear from you. Take this survey and share your thoughts with us. This article originally appeared on Delaware News Journal: Sussex County home listings asked for more money in May
Yahoo
11 minutes ago
- Business
- Yahoo
New Castle County home listings asked for more money in May - see the current price here
The median home in New Castle County listed for $425,000 in May, up 3.7% from the previous month's $409,950, an analysis of data from shows. Compared with May 2024, the median home list price decreased 4.3% from $452,068. The statistics in this article only pertain to houses listed for sale in New Castle County, not houses that were sold. Information on your local housing market, along with other useful community data, is available at New Castle County's median home was 2,002 square feet, listed at $211 per square foot. The price per square foot of homes for sale is mostly unchanged from May 2024. Sussex County : Home listings asked for more money in May - see the current median price here Kent County: Home listings asked for less money in May - see the current median price here Listings in New Castle County moved briskly, at a median 31 days listed compared with the May national median of 51 days on the market. In the previous month, homes had a median of 29 days on the market. Around 596 homes were newly listed on the market in May, a 3.1% increase from 578 new listings in May 2024. The median home prices issued by may exclude many, or even most, of a market's homes. The price and volume represent only single-family homes, condominiums or townhomes. They include existing homes, but exclude most new construction as well as pending and contingent sales. Across the Philadelphia-Camden-Wilmington metro area, median home prices rose to $385,000, slightly higher than a month earlier. The median home had 1,616 square feet, at a list price of $233 per square foot. In Delaware, median home prices were $499,000, a slight increase from April. The median Delaware home listed for sale had 2,100 square feet, with a price of $238 per square foot. Throughout the United States, the median home price was $440,000, a slight increase from the month prior. The median American home for sale was listed at 1,840 square feet, with a price of $234 per square foot. The median home list price used in this report represents the midway point of all the houses or units listed over the given period of time. Experts say the median offers a more accurate view of what's happening in a market than the average list price, which would mean taking the sum of all listing prices then dividing by the number of homes sold. The average can be skewed by one particularly low or high price. The USA TODAY Network is publishing localized versions of this story on its news sites across the country, generated with data from Please leave any feedback or corrections for this story here. This story was written by Ozge Terzioglu. Our News Automation and AI team would like to hear from you. Take this survey and share your thoughts with us. This article originally appeared on Delaware News Journal: New Castle County home listings asked for more money in May
Yahoo
11 minutes ago
- Business
- Yahoo
Kent County home listings asked for less money in May - see the current median price here
The median home in Kent County listed for $408,500 in May, down 1.6% from the previous month's $415,000, an analysis of data from shows. Compared with May 2024, the median home list price decreased 3.9% from $425,000. The statistics in this article only pertain to houses listed for sale in Kent County, not houses that were sold. Information on your local housing market, along with other useful community data, is available at Kent County's median home was 1,972 square feet, listed at $208 per square foot. The price per square foot of homes for sale is up 3.5% from May 2024. Listings in Kent County moved steadily, at a median 38 days listed compared with the May national median of 51 days on the market. In the previous month, homes had a median of 46 days on the market. Around 240 homes were newly listed on the market in May, a 7.1% increase from 224 new listings in May 2024. The median home prices issued by may exclude many, or even most, of a market's homes. The price and volume represent only single-family homes, condominiums or townhomes. They include existing homes, but exclude most new construction as well as pending and contingent sales. Sussex County: Home listings asked for more money in May - see the current median price here New Castle County: Home listings asked for more money in May - see the current median price here Across the Philadelphia-Camden-Wilmington metro area, median home prices rose to $385,000, slightly higher than a month earlier. The median home had 1,616 square feet, at a list price of $233 per square foot. In Delaware, median home prices were $499,000, a slight increase from April. The median Delaware home listed for sale had 2,100 square feet, with a price of $238 per square foot. Throughout the United States, the median home price was $440,000, a slight increase from the month prior. The median American home for sale was listed at 1,840 square feet, with a price of $234 per square foot. The median home list price used in this report represents the midway point of all the houses or units listed over the given period of time. Experts say the median offers a more accurate view of what's happening in a market than the average list price, which would mean taking the sum of all listing prices then dividing by the number of homes sold. The average can be skewed by one particularly low or high price. The USA TODAY Network is publishing localized versions of this story on its news sites across the country, generated with data from Please leave any feedback or corrections for this story here. This story was written by Ozge Terzioglu. Our News Automation and AI team would like to hear from you. Take this survey and share your thoughts with us. This article originally appeared on Delaware News Journal: Kent County home listings asked for less money in May
Sustainability Times
9 hours ago
- Science
- Sustainability Times
'US Navy Breaks the Silence': World's First Reusable Underwater Spy Robot Deployed on Nuclear Submarine
IN A NUTSHELL 🔍 The US Navy has successfully deployed and recovered the world's first reusable spy robot, the Yellow Moray , from a nuclear submarine. , from a nuclear submarine. 🤖 This achievement marks a significant advancement in naval technology, allowing submarines to extend capabilities using robotic systems without risking human lives. without risking human lives. 🌊 The Yellow Moray autonomously conducted missions lasting 6 to 10 hours, proving the Navy's ability to use unmanned systems multiple times in one deployment. autonomously conducted missions lasting 6 to 10 hours, proving the Navy's ability to use unmanned systems multiple times in one deployment. ⚓ This operation underscores the strategic importance of robotic systems in future undersea missions, offering more options while minimizing risks to sailors. In a groundbreaking advancement for naval operations, the US Navy has successfully integrated unmanned technology into its submarine missions. This significant achievement involves the deployment and recovery of an unmanned underwater vehicle (UUV) from a nuclear-powered submarine. The USS Delaware, a Virginia-class attack submarine, served as the platform for this innovative operation. Known as the Yellow Moray, this reusable spy robot marks a pivotal moment in undersea warfare, demonstrating the Navy's commitment to enhancing its operational capabilities while minimizing risks to personnel. This article delves into the details of this milestone mission, exploring the implications and future potential of such technology in military applications. World's First Reusable Spy Robot for Submarines The recent mission took place in the US European Command (EUCOM) area of operations and featured the Virginia-class nuclear attack submarine USS Delaware (SSN 791). This successful test signifies a formidable leap in naval technology, as submarines can now enhance their capabilities using robotic systems without endangering divers or crew members. The Yellow Moray is based on the REMUS 600, a well-established UUV design used for various underwater missions, including seafloor mapping and intelligence gathering. This torpedo-shaped robot can autonomously carry out missions, operating independently of human control once launched. During this deployment, the USS Delaware launched and recovered the Yellow Moray robot three times, with each mission lasting between 6 and 10 hours. All operations utilized the submarine's torpedo tube, a traditional launch system for torpedoes. This operation demonstrated the Navy's capacity to use the same UUV multiple times in one deployment, enabling the execution of missions in areas too shallow or hazardous for submarines. Moreover, the elimination of divers in launching and recovery processes further underscores the Navy's ability to conduct safe and efficient operations with minimal human involvement. Spy and Return in Secret This mission illustrates the US Navy's readiness to integrate manned submarines with advanced robotic systems in real-world scenarios. These robotic vehicles can access areas deemed risky or impossible for submarines, undertaking missions that are either too mundane or dangerous for human personnel. Tasks such as scanning the seabed for mines, conducting surveillance, or scouting enemy waters can now be performed more effectively. 'This capability allows us to extend our reach,' stated Vice Admiral Rob Gaucher, Commander of Submarine Forces. 'The Yellow Moray reduces risk to our submarines and divers by handling dull, dirty, and dangerous missions.' The initial tests weren't without challenges. During early trials in a Norwegian fjord, the Yellow Moray failed to return to the torpedo tube due to a damaged part. Despite this setback, the Navy swiftly adapted by repairing the robot and resuming successful operations from the USS Delaware. This adaptability highlights the Navy's ability to maintain flexibility and mobility in future operations, emphasizing the strategic importance of robotic systems in future undersea missions. Technological Adaptation and Future Prospects The Navy's ability to quickly diagnose and repair the Yellow Moray underlines the importance of technological resilience in military operations. Technicians identified the damaged component and returned the robot to the US for necessary repairs. Post-repair, the robot was flown back to Europe and successfully launched and recovered in subsequent missions from the USS Delaware. This swift adaptation ensures that missions remain on schedule, demonstrating the Navy's readiness to overcome obstacles and maintain operational integrity. In a notable first, Navy divers loaded the Yellow Moray into the submarine via the torpedo tube while docked in Norway, proving that future missions could remain flexible and adaptable. The Navy's commitment to equipping more submarines with robotic systems like the Yellow Moray signifies a shift towards a more autonomous and resilient naval force. This mission reinforces the notion that the future of submarine warfare is not only underwater but also robotic, offering commanders expanded operational options while minimizing risks to sailors. Implications for Future Naval Warfare The integration of robotic systems into naval operations presents significant implications for the future of warfare. The ability to deploy and recover UUVs like the Yellow Moray from submarines enhances the Navy's strategic capabilities, providing commanders with a versatile tool for diverse missions. This technology also opens new avenues for intelligence gathering and reconnaissance, allowing the Navy to operate in previously inaccessible or high-risk areas. The Yellow Moray's success suggests that future naval missions will increasingly rely on robotic and autonomous systems to undertake tasks that are too dangerous or impractical for humans. As the Navy continues to develop and integrate these technologies, it will inevitably reshape the landscape of undersea warfare. This evolution raises an intriguing question: How will the continued advancement of robotic technology redefine the boundaries of naval operations in the coming decades? Our author used artificial intelligence to enhance this article. Did you like it? 4.6/5 (25)
Yahoo
12 hours ago
- Business
- Yahoo
Incyte replaces CEO Hoppenot with dealmaker Meury
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Incyte has named veteran pharmaceutical executive Bill Meury as its new CEO, replacing longtime head Hervé Hoppenot, who led the cancer and blood disease drugmaker for the past 11 years. Meury, whose appointment is effective immediately, previously ran Anthos Therapeutics, which he sold this year to Novartis for nearly $1 billion, and Karuna Therapeutics, which Bristol Myers Squibb bought for $14 billion in 2023. Prior to those posts, Meury was chief commercial officer at Allergan. Hoppenot will remain on Incyte's board of directors through the end of this year to aid Meury's transition into the CEO role. Alongside the succession, Julian Baker, managing partner of biotechnology investor Baker Bros. Advisors and lead independent director for Incyte, was elected board chair. Much of Hoppenot's time at Incyte focused on what he once described as 'single asset syndrome.' The company has had a good deal of success with Jakafi, a multipurpose drug approved to treat rare blood cancers and graft-versus-host disease. Last year, Jakafi brought in nearly $2.8 billion in sales. But Jakafi's main patents expire in 2028, a date that for years now has been on investors' radar as they've pressed Incyte on what it expects will take the drug's place. Early in Hoppenot's tenure, the answer looked like a cancer medicine called epacadostat, which Incyte believed could become a cornerstone of immunotherapy combinations. However, it flamed out in testing in 2018 and Incyte was forced to pivot research toward other candidates. Since then, Incyte has had some success building out its portfolio. The company now owns six other approved drugs, including a cream formulation of Jakafi's main ingredient that's proved useful treating atopic dermatitis and vitiligo. 'Hervé joined Incyte in 2014 when it was a single product, U.S.-only company,' said board member Baker, in a statement. 'During Hervé's tenure, Incyte launched six novel medicines plus two new indications for Jakafi, expanded commercial operations into Europe, Japan and Canada and grew revenues from $355 million dollars in 2013 to $4.2 billion today.' However, Incyte's other drugs don't make it much money. Jakafi and the cream formulation of the drug Incyte sells as Opzelura accounted for 91% of net product revenues last year. (The company also earned nearly $600 million in royalty revenues.) Stephen Willey, an analyst at Stifel, gives Hoppenot credit for increasing Incyte revenues by more than 10 times during his time as CEO. But, in a Thursday note to clients, he added that some investors grew frustrated with the company's high research and development spending without a clear post-Jakafi plan. Shaping those plans will now fall to Meury, who gained industry visibility by guiding his prior two companies to lucrative acquisitions. 'We expect the immediate reaction from investors will be an expectation that [Incyte] could now become an M&A target, simply because Mr. Meury sold Anthos ... and sold [Karuna],' wrote RBC Capital Markets analyst Brian Abrahams, in a note to clients. Shares in Incyte, which have fallen by 30% over the past five years, rose by more than 4% in Thursday morning trading on the CEO news. 'It has been a privilege to lead Incyte over the past eleven years,' Hoppenot said in the company's statement. 'I am proud to retire at a time when Incyte has the strongest management team, internal R&D pipeline and commercial portfolio ever.' Incyte expects multiple pivotal trial readouts this year, along with proof-of-concept data for several pipeline candidates. Recommended Reading Unblinded: Hervé Hoppenot on solving Incyte's 'single asset syndrome' Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
